Even better than semaglutide...

Novo Nordisk is spruiking new trial data showing its next-generation obesity treatment CagriSema has significantly outperformed semaglutide in key metrics.

The head-to-head REIMAGINE 2 trial pitted CagriSema, a combination of semaglutide and novel amylin receptor agonist cagrilintide, against the basis of its current obesity and diabetes portfolio, semaglutide alone.

"We are very pleased by the clinical profile of CagriSema in type 2 diabetes patients, including a confirmation of the very strong weight loss data seen with CagriSema in the obesity trials," Novo EVP, CSO, and Head of Research and Development, Martin Holst Lange, said.